KLK3 and cancer: Most importantly, because u-PSA may improve the time to detection as a supplement to t-PSA of BCR by months or years, this advantage of earlier prediction for relapse has potential to improve the patients’ chance of durable progression-free survival with salvage therapy given at a lower cancer burden and a wider time window for cure4, 31.